- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02975505
Pilot to Examine Risk and Feasibility of Remote Management of BP From CKD Through ESRD (PERFORMANCE)
July 1, 2022 updated by: University of California, San Francisco
The transition from chronic kidney disease (CKD) to end-stage renal disease ESRD is a vulnerable and challenging period of time for patients and providers.
Suboptimal control of blood pressure is known to be common in patients with the advanced stages of CKD, and may contribute to their elevated risk of progression to ESRD, cardiovascular morbidity, and mortality.
This proposal is a pilot randomized controlled trial designed to test whether intensive blood pressure lowering is feasible and safe in patients with advanced CKD as they transition to ESRD.
Study Overview
Status
Suspended
Conditions
Intervention / Treatment
Detailed Description
The transition from advanced chronic kidney disease (CKD), when estimated glomerular filtration rate (eGFR) is <=30 mL/min/1.73m2,
to end-stage renal disease (ESRD) represents a vulnerable period, when multiple physiologic and psychosocial changes occur as patients prepare for either dialysis or kidney transplant.
This study is a pilot randomized controlled trial to test the safety and feasibility of studying strict versus usual BP control in a population of patients with advanced CKD (eGFR <=30 mL/min/1.73m2),
including those with diabetes.
For this pilot study, we will randomize 120 patients with advanced CKD who have elevated BP to either a home SBP target of <120 mm Hg (intervention group) versus 130-140 mm Hg (usual care group).
Study Type
Interventional
Enrollment (Anticipated)
200
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
San Francisco, California, United States, 94143
- University of California, San Francisco
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
Adults ≥16 years of age who meet the eGFR eligibility criteria, which will be determined based on whether participants have
- at least two eGFR in the last three months that are <=30 mL/min/1.73m2 or
- prior diagnosis of CKD (per electronic chart review) and at least one eGFR <=30 mL/min/1.73m2
- history of hypertension
- mid-arm circumference between 22-37cm (BP cuff size limitation) and be able to provide consent to participate in our study.
Exclusion criteria
Those who:
- are or are planning to become pregnant, due to inability to take multiple classes of anti-hypertensive agents
- are marginally housed, due to concerns regarding routine follow-up
- are actively participating in a different interventional trial that may affect blood pressure
- are unwilling to consent to participate
- institutionalized individuals or prisoners
- are actively abusing illicit drugs or alcohol
- have a history of poor or doubtful compliance (e.g., frequently missed appointments)
- have office SBP >170 mmHg
- are already taking >5 anti-hypertensive medications (any classes, including diuretics) have cognitive impairment prohibiting participation in the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Strict SBP Target
Target Systolic Blood Pressure <120 mm Hg
|
Systolic Blood Pressure Target < 120 mm Hg (measured at home)
|
No Intervention: Usual SBP Target
Target Systolic Blood Pressure 130-140 mm Hg
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Hyperkalemia
Time Frame: Months 1-12 and study end
|
Hyperkalemia: This will be defined as a non-hemolyzed potassium ≥6.0 meq/L.
|
Months 1-12 and study end
|
Achieved Blood Pressure
Time Frame: Months 4-12 and study end
|
Months 4-12 and study end
|
|
Falls and syncope by self-report or based on emergency room visits
Time Frame: Months 1-12 and study end
|
Falls and syncope: This will be defined based on self-report or if either is the chief complaint for an ER visit.
|
Months 1-12 and study end
|
End-stage Renal Disease
Time Frame: Month 1 to study end
|
Defined as receipt of chronic dialysis or kidney transplant
|
Month 1 to study end
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants screened who enroll in trial
Time Frame: Months 0-12
|
Feasibility of enrollment
|
Months 0-12
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Raymond Hsu, MD MAS, University of California, San Francisco
- Principal Investigator: Elaine Ku, MD MAS, University of California, San Francisco
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 10, 2017
Primary Completion (Anticipated)
July 1, 2026
Study Completion (Anticipated)
July 1, 2026
Study Registration Dates
First Submitted
November 22, 2016
First Submitted That Met QC Criteria
November 28, 2016
First Posted (Estimate)
November 29, 2016
Study Record Updates
Last Update Posted (Actual)
July 6, 2022
Last Update Submitted That Met QC Criteria
July 1, 2022
Last Verified
July 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 16-20978
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertension
-
National Taiwan University Hospital Hsin-Chu BranchRecruitingHypertension,Essential | Hypertension, MaskedTaiwan
-
University of Alabama at BirminghamTroy UniversityCompletedHypertension | Hypertension, Resistant to Conventional Therapy | Uncontrolled Hypertension | Hypertension, White CoatUnited States
-
BayerCompletedPrimary HypertensionChina
-
Addpharma Inc.Completed
-
Columbia UniversityAgency for Healthcare Research and Quality (AHRQ)Active, not recruitingWhite Coat Hypertension | Hypertension,EssentialUnited States
-
Universidade Federal de Santa MariaCompletedHealthy Volunteers | Hypertension, EssentialBrazil
-
Sulaiman AlRajhi CollegesUnknownHypertension, Essential | β-hydroxybutyrate
-
Centre Chirurgical Marie LannelongueUnknownChronic Thrombo-embolic Pulmonary Hypertension and Pulmonary Arterial HypertensionFrance
-
Sheffield Teaching Hospitals NHS Foundation TrustUniversity of SheffieldCompletedIdiopathic Pulmonary Arterial Hypertension | Chronic Thromboembolic Pulmonary HypertensionUnited Kingdom
Clinical Trials on Strict blood pressure control
-
University of California, San FranciscoCompletedHypertension | Chronic Kidney Diseases | Blood PressureUnited States
-
The University of Texas Health Science Center,...National Institutes of Health (NIH)Terminated
-
Vancouver Coastal HealthWithdrawnDiabetes Mellitus, Type 1 | Islet TransplantationCanada
-
Children's Hospital of PhiladelphiaWithdrawnSepsis | Respiratory Failure | Trauma | Cardiovascular Failure
-
The Second Affiliated Hospital of Chongqing Medical...RecruitingMonotherapy | Hypertensive PatientsChina
-
University Medical Center GroningenNetherlands Heart FoundationCompleted
-
Vanderbilt University Medical CenterSarah Osmundson, MD, MS; Alex Phelps, MD; Julia Phillippi, PhD, CNM; Soha Patel... and other collaboratorsRecruitingHypertension, Pregnancy-Induced | Postpartum Preeclampsia | Hypertension; MaternalUnited States
-
University of ZurichCompleted
-
Wake Forest University Health SciencesNational Center for Advancing Translational Sciences (NCATS)Completed
-
Northwestern UniversityNational Heart, Lung, and Blood Institute (NHLBI)CompletedCardiopulmonary Bypass | Thoracic SurgeryUnited States